Chest U/S in Differentiating Lung Congestion & Pneumonia in Adult Critically-ill Patients and Its Prognostic Impact

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05636631
Collaborator
(none)
60
1
33
1.8

Study Details

Study Description

Brief Summary

This study aim will be to assess the effectiveness of chest ultrasound as a diagnostic and differentiating modality in cases of pneumonia and lung congestion . It also evaluates chests sonography effectiveness in follow-up of patients with pneumonia and lung congestion .

Condition or Disease Intervention/Treatment Phase
  • Device: Chest ultrasound

Detailed Description

Lung ultrasound (LUS) is used at the bedside in emergency and critical care settings. It is a rapid and low-cost approach that can direct patient care without the use of harmful radiation. The success of this technique depends on its simplicity to discover the sonographic signs which indicate certain lung pathology. These signs include a hyperechoic and sliding line, moving forward and back with ventilation seen 0.5 cm below the rib line and is called the pleural line. The A-profile associates anterior lung sliding with A lines. A lines are horizontal repetition artifacts of the pleural line. The B-profile associates anterior lung sliding with B lines. B lines appear as shining vertical lines arising from the pleural line and reach the edge of the screen.

Several pathological etiologies can fill the alveolar spaces, with fluid (heart failure), pus (pneumonia which is the commonest), blood (pulmonary hemorrhage), and cells (lung cancer).

Other causes of lung consolidation may include atelectasis, pulmonary edema, infarction, and lung cancer. Chest imaging with CT is regarded as the gold standard modality allowing for the diagnosis of pneumonia in earlier stage and with higher sensitivity and specificity. On the contrary, cardiogenic pulmonary edema (CPE) is defined as alveolar transudation caused by elevated pulmonary capillary hydrostatic pressure secondary to increased pulmonary venous pressure with low-protein content in the interstitial tissue of lung as a result of cardiac dysfunction

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Role of Chest Ultrasound in Differentiating Lung Congestion and Pneumonia in Adult Critically-ill Patients and Its Prognostic Impact
Actual Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Nov 30, 2024
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Patients with Pneumonia (1)

Patients presented with symptoms suggestive of pneumonia as fever, tachypnea, cough with sputum. These patients will receive IV fluids & antibiotics with follow up of sepsis parameters

Device: Chest ultrasound
chest ultrasound as a non invasive, low cost & bedside device for differentiation & follow up of lung congestion & pneumonia

Patients with decongestive heart failure (2)

Patients presented with symptoms suggestive of acute congestive heart failure as dyspnea, orthopnea, bilateral lower limb edema. These patients will receive anti-failure treatment as diuretics, ACE inhibitors & Beta blockers with follow up of resolving signs of decompensated heart failure

Device: Chest ultrasound
chest ultrasound as a non invasive, low cost & bedside device for differentiation & follow up of lung congestion & pneumonia

Outcome Measures

Primary Outcome Measures

  1. Diagnostic tool [Baseline]

    Diagnosis of pneumonia vs lung congestion by using chest ultrasound examination viewing A-lines, B-lines, pleural effusion presence & its initial amount .

  2. Follow up after initiation of treatment [Baseline ( day 3 of hospital admission)]

    Follow up of findings of chest U.S on day 1 after initiating therapy using same parameters ( A-lines, B-lines, pleural effusion) on day 3 of hospital admission

  3. Follow up before assessing final outcome [Baseline ( day 7 of hospital admission)]

    Follow up of findings of chest U.S on day 1 after initiating therapy using same parameters ( A-lines, B-lines, pleural effusion) on day 7 of hospital admission

Secondary Outcome Measures

  1. morbidity & mortality [baseline]

    if patient's symptoms improved or not If patient died or not

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult (above 18 years old)

  • Both genders

  • Patient with symptoms suggestive of pneumonia

  • Patient with symptoms suggestive of acute congestive heart failure

  • admitted to Critical care unit

Exclusion Criteria:
  • Patients with Renal induced lung congestion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nardin Aymn Assiut Asyut Egypt 71511

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Director: Mahmoud Ashry, Professor, Professor Faculty of Medicine, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nardin Aymn Boshra, Doctor, Assiut University
ClinicalTrials.gov Identifier:
NCT05636631
Other Study ID Numbers:
  • chest US for lung conditions
First Posted:
Dec 5, 2022
Last Update Posted:
Dec 5, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 5, 2022